Placing, Launch of Vault Accelerator and PDMRs

Vault Ventures Plc (AQSE: VULT) has raised £555,000 through an over‑subscribed placing of 55.5m new ordinary shares at 1p each, issued 111m attaching placing warrants exercisable at 1p for three years (plus 1.02m broker warrants), with admission to AQSE expected around 19 December 2025 and total issued share capital rising to 321,010,846. The funds will support the launch of a Vault Accelerator focused on blockchain, AI, augmented reality and early‑stage quantum technologies intended to deliver recurring programme and advisory revenue while building selective minority equity positions to drive longer‑term NAV growth; the placing included subscriptions from Chairman Brian Stockbridge and Director Derek Lew, constituting a related‑party transaction. Management also notes a treasury holding of 818.85 ETH (c. £1.89m) plus cash that together exceed the company’s current market capitalisation, providing balance‑sheet support even as warrants and new issuance create potential dilution.

Analysis

Vault Ventures Plc completed an over-subscribed placing raising £555,000 by issuing 55,500,000 new ordinary shares at 1p each and attaching 111,000,000 placing warrants exercisable at 1p for three years, plus 1,020,000 broker warrants; admission to AQSE is expected around 19 December 2025 and the company's issued share capital will total 321,010,846 ordinary shares post-admission. The Placing is presented as funding for a strategic shift from ad-hoc projects to a structured Vault Accelerator focused on blockchain, AI, augmented reality and early-stage quantum technologies, with management forecasting recurring programme and advisory revenue alongside selective minority equity stakes to drive NAV growth. Management highlights a treasury holding of 818.85 ETH (c. £1.89m) and available cash such that combined liquid assets exceed the company’s current market capitalisation, providing immediate balance-sheet support while the accelerator is implemented. Key risks include meaningful potential dilution from warrants (full dilution would push the share count to roughly 433.03m if exercised), execution risk on converting accelerator interest into revenue and illiquid early-stage equity, and governance scrutiny after related-party subscriptions by the chairman and a director despite the board’s fairness statement.

Key Decisions for Investors

• Treat VULT as a high-risk, early-stage speculative exposure and limit position size to capital you can afford to lock up until the Accelerator demonstrates concrete programme revenue or portfolio value realisations
• Monitor near-term operational catalysts—formation of the first cohort, announcements of programme fees or advisory contracts, and any follow-on funding or exits from portfolio companies—and reassess conviction only after these are evidenced
• Closely track capital structure developments and warrant activity (111m placing warrants plus 1.02m broker warrants); model the impact of exercise at 1p on per-share NAV and consider hedging or reducing exposure if dilution is realised without commensurate NAV uplift
• Demand clearer governance and valuation disclosure around related-party subscriptions and minority equity stakes before increasing exposure, and be prepared to exit or reduce weighting if execution or transparency lapses